Results 21 to 30 of about 1,150,912 (211)

Liver cirrhosis [PDF]

open access: yesPostgraduate Medical Journal, 1998
Summary Liver fibrosis and its related complications continue to represent a significant worldwide healthcare burden. Over the past decade there has been considerable improvement in our understanding of the cellular mechanisms and pathophysiology underlying hepatic fibrosis.
E J, Williams, J P, Iredale
openaire   +2 more sources

Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis

open access: yesBMC Gastroenterology, 2021
Background and aim Hemostasis profile is often complicated in liver cirrhosis. Thromboelastography is a global viscoelastic test recommended by the current practice guideline and consensus.
Yanglan He   +8 more
doaj   +1 more source

Serum microRNA-122 predicts survival in patients with liver cirrhosis [PDF]

open access: yes, 2012
Background: Liver cirrhosis is associated with high morbidity and mortality. MicroRNAs (miRs) circulating in the blood are an emerging new class of biomarkers.
Stefan Zeuzem   +23 more
core   +2 more sources

Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. [PDF]

open access: yes, 2008
BACKGROUND: Cirrhosis of the liver is thought to be a major cause of morbidity and mortality in sub-Saharan Africa, but few controlled studies on the etiology of cirrhosis have been conducted in this region.
James J. Goedert   +21 more
core   +1 more source

Drug-related problems and dosage adjustment in patients with liver disease [PDF]

open access: yes, 2012
The liver is essential for the metabolism of medicinal substances. Liver disease, especially liver cirrhosis, may lead to various pharmacokinetic and pharmacodynamic changes, predisposing patients with liver cirrhosis to adverse drug events (ADEs).
Franz, Carmen Carina
core   +1 more source

Liver transplantation in primary biliary cirrhosis: Risk assessment and 11-year follow-up [PDF]

open access: yes, 2000
Background/Aims: Liver transplantation (LTx) is the only established treatment in patients with end-stage primary biliary cirrhosis (PBC). Although short-term survival after LTx in this group of patients is usually good, few data exist on the long-term ...
Paumgartner, Gustav   +8 more
core   +1 more source

Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis

open access: yesArchives of Medical Science, 2019
Introduction Spider nevus and subcutaneous collateral vessel of the chest/abdominal wall are common in liver cirrhosis. This prospective study aimed to evaluate the impact of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall on ...
Hongyu Li   +5 more
doaj   +1 more source

Intrarenal Resistance Index as a Prognostic Parameter in Patients with Liver Cirrhosis Compared with Other Hepatic Scoring Systems [PDF]

open access: yes, 2012
Background and Aims: Patients with advanced liver cirrhosis who develop renal dysfunction have a poor prognosis. Elevated intrarenal resistance indices (RIs) due to renal vascular constriction have been described before in cirrhotic patients.
Kaiser, C.   +7 more
core   +1 more source

Atrial natriuretic factor (ANF) and renin-aldosterone in volume regulation of patients with cirrhosis [PDF]

open access: yes, 1989
The role of the atrial natriuretic factor and of the main counteracting sodium-retaining principle, the renin-aldosterone system, in acute volume regulation of cirrhosis of the liver has been investigated.
Arendt, Rainer M.   +5 more
core   +1 more source

Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients

open access: yesOrphanet Journal of Rare Diseases, 2022
Background and aims Immunoglobulin G4-related disease (IgG4-RD) is a multisystem fibroinflammatory condition. The aim of the present study was to characterize the clinical features and therapeutic response of patients with IgG4-RD and identify risk ...
Wen An   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy